rivastigmine has been researched along with Bone Loss, Osteoclastic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, C; Inderjeeth, CA; Li, S; Liu, L; Teguh, D; Wu, D; Xu, J; Yuan, J | 1 |
1 other study(ies) available for rivastigmine and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.
Topics: Acetylcholinesterase; Animals; Bone Resorption; Cell Differentiation; Cholinesterase Inhibitors; Donepezil; Female; Humans; Mice; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; RANK Ligand; Rivastigmine; Transcription Factors; X-Ray Microtomography | 2023 |